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Abstract
Background: Small molecule modulators of epigenetic processes are currently sought as basic probes for biochemical
mechanisms, and as starting points for development of therapeutic agents. N
e-Methylation of lysine residues on histone
tails is one of a number of post-translational modifications that together enable transcriptional regulation. Histone lysine
demethylases antagonize the action of histone methyltransferases in a site- and methylation state-specific manner. N
e-
Methyllysine demethylases that use 2-oxoglutarate as co-factor are associated with diverse human diseases, including
cancer, inflammation and X-linked mental retardation; they are proposed as targets for the therapeutic modulation of
transcription. There are few reports on the identification of templates that are amenable to development as potent
inhibitors in vivo and large diverse collections have yet to be exploited for the discovery of demethylase inhibitors.
Principal Findings: High-throughput screening of a ,236,000-member collection of diverse molecules arrayed as dilution
series was used to identify inhibitors of the JMJD2 (KDM4) family of 2-oxoglutarate-dependent histone demethylases. Initial
screening hits were prioritized by a combination of cheminformatics, counterscreening using a coupled assay enzyme, and
orthogonal confirmatory detection of inhibition by mass spectrometric assays. Follow-up studies were carried out on one of
the series identified, 8-hydroxyquinolines, which were shown by crystallographic analyses to inhibit by binding to the active
site Fe(II) and to modulate demethylation at the H3K9 locus in a cell-based assay.
Conclusions: These studies demonstrate that diverse compound screening can yield novel inhibitors of 2OG dependent
histone demethylases and provide starting points for the development of potent and selective agents to interrogate
epigenetic regulation.
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Introduction
N
e-Methylation of lysine residues on histone tails is an
important post-translational modification in transcriptional regu-
lation. Lysine residues in histones are methylated and demethyl-
ated by sequence-specific methyltransferases and demethylases.
The dynamic interplay between these, and other, enzyme classes is
an important process in the control of chromatin structure and
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15535transcriptional activity (for review see [1,2,3]). Specific histone
lysine methylation sites (e.g. histone H3K4 methylation) are, in
general, associated with the promoters of actively transcribed
genes [4], whereas other methylation sites (e.g. histone H3K9
methylation) are associated with heterochromatic regions of the
genome [5]. A molecular understanding of the enzymes that place
and remove histone modifications, and the proteins that bind to
them, is only beginning to emerge. In several instances, mutations
of genes encoding histone modifying enzymes have been linked
with diseases, including cancers, mental retardation, and midline
defects (reviewed in [6,7,8]).
Small-molecule inhibitors of the catalytic activity of histone-
modifying enzymes are of interest both as therapeutic agents, as
shown by the clinically-approved histone deacetylase inhibitors
Vorinostat and Romidepsin [9], and as chemical probes for
investigating biological function. Biological techniques such as RNA
interference are useful in functional assignment work, but are of
limited use when proteins have separate functional domains. Many
histone-modifying enzymes contain various domains in addition to a
catalytic domain, including those involved in DNA-binding and
protein-protein interactions. There is thus an unmet need for the
development of small molecule inhibitors of catalytic activity that allow
the other functions of histone-modifying proteins to remain intact.
The jumonji-C (JmjC) domain-containing enzymes constitute
the largest class of histone demethylases, and the family is
predicted to include about 30 human members. These enzymes
utilize Fe(II) in a 2-oxoglutarate-dependent dioxygenase mecha-
nism to remove methyl groups from methylated lysines of histone
tails. JmjC-domain demethylases are linked with diseases,
including androgen-dependent prostate cancer [10], obesity [11],
and X-linked metal retardation [12], suggesting that these
enzymes may constitute novel targets for therapeutic intervention.
To date only few inhibitor scaffolds for the 2-oxoglutarate
(2OG) dependent histone lysine demethylases have been described
and the available structure-activity data are limited [13,14,15].
Identified inhibitors predominantly include 2OG mimetics, such
as 2,4-pyridinedicarboxylic acid (PDCA), a fragment-size JmjC-
domain inhibitor of micromolar potency, which needs to be
modified to a prodrug form in order to enable penetration of cell
membranes [16] and functionalised hydroxamic acids [17]. A
recent screen of a small-size bioactives collection [18] yielded
primarily flavonoid and catechol type molecules; these are known
iron chelators and represent promiscuous inhibitors affecting a
wide range of molecular targets. However, this work suggests that
screening a large and diverse collection for chemotypes amenable
to further optimization may be useful. Here we report the
application of quantitative high-throughput screening (qHTS) [19]
to identify new series of inhibitors of histone demethylases. A
diverse collection of ,236,000 compounds was screened in
concentration-response format by using a real-time fluorogenic
coupled assay designed to monitor formaldehyde production from
the demethylation reaction. One of the hit series, the 8-
hydroxyquinolines (8HQs), demonstrates clear structure activity
relationships and is here presented as a good template from which
selective inhibitors may be designed. Furthermore, we show that
8HQs inhibit JMJD2 via binding to the active-site iron and display
activity against JMJD2A in cell-based studies.
Results
Quantitative High-Throughput Screen and Hit
Prioritization
We have reported a miniaturized fluorescence-based assay [20]
for high-throughput screening of histone demethylase inhibitors
[18]; this assay detects formaldehyde released from the demethy-
lase reaction by converting it to formic acid using formaldehyde
dehydrogenase [21]. The oxidation of formaldehyde is coupled to
the reduction of NAD
+ to NADH, which is monitored by
fluorescence spectroscopy. In order to identify histone demethylase
inhibitor templates, we applied this assay for high-throughput
screening of a diverse compound library, comprising the
Molecular Libraries Small Molecule Repository (MLSMR) and
additional collections, against the 2OG-dependent histone de-
methylase JMJD2E (KDM4E). JMJD2E was chosen as a
representative member of the JMJD2 histone demethylase
subfamily with kinetic properties suitable for in vitro high-
throughput screening. Approximately 236,000 compounds were
evaluated in a concentration-response screen using a robotic
system. The results of the screen of 1,316 plates were statistically
robust, with an average Z9 factor of 0.85 (Figure S1), and the
screen was completed within 5 days. The screen yielded hits with a
wide range of potencies (IC50) and with substantial variation in the
quality of the corresponding concentration-response curves
(efficacy and number of asymptotes), which included samples
associated with shallow curves or single-point extrapolated
concentration responses; these were assigned as low-confidence
actives. Furthermore, the screening results were expected to be
affected by interferences arising from factors including compound
autofluorescence, noisy/partial concentration responses, false
positives acting on the coupled-enzyme component of the assay,
and promiscuous inhibitors or potent metal chelators. To this end,
initial screening hits were filtered by a combination of cheminfor-
matics (to exclude low-confidence inhibitors and autofluorescent
false positives), counterscreening against the coupled-assay com-
ponent formaldehyde dehydrogenase (FDH), and orthogonal
direct detection of inhibition of demethylation by mass spectrom-
etry (Figure 1).
Only samples which displayed greater than 40% inhibition at
the highest concentration tested were considered as active hits,
thus eliminating compounds associated with noisy data and weak
partial curves. The initial fluorescence reading for each sample
was used to identify compounds contributing high background
fluorescence. An arbitrary initial fluorescence reading of 50
relative fluorescence units (RFU) was selected in order to balance
the threshold for statistical significance and the need to flag
artifacts as rigorously as possible; this represents the average
assay signal plus three standard deviations. This was used as
a cutoff for exclusion of autofluorescent hits. Application of this
step eliminated 21,674 of the actives, a large but not un-
expected number due to the blue spectral region of the detection
signal [22]. Similarity clustering of the remaining 3,597 actives
led to 51 clusters and over 150 singletons. Upon further
filtering by potency (cutoff of IC50,10 mM and cluster size
greater than 4), a total of 157 representative compounds spanning
17 chemical clusters and 83 singletons were prioritized for further
studies.
The selected compounds were then tested to evaluate their
effect on the FDH coupling enzyme used for formaldehyde
detection. The prioritized compounds were also evaluated in the
screening assay using two different ferrous ion concentrations
(termed high iron and low iron, respectively), in order to assess
their propensity for iron chelation. The results for selected hit
series are presented in Figure 2 (including examples of
autofluorescent compounds, such as SID 77817010 and
17408386, some of which otherwise carry attractive chemical
features), with the full set of screening results being made freely
available in PubChem (PubChem Assay ID 2147). The results for
the 157 representative compounds are provided in Table S1.
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displayed inhibition of the coupling enzyme FDH (e.g. the thiazolo
triazolones and pyrrolidine-2,5-dione series, Figure 2). This
outcome is consistent with a previously-reported screen of the
LOPAC
1280 collection where none of the hits inhibited FDH [18]
and with the fact that during the HTS FDH is applied at a
concentration approximately 10 times greater than that used in the
counterscreen (the counterscreen uses lower FDH concentration in
order to maintain reaction linearity and to match the amount of
NADH product generated by the two assays). Assaying the
prioritized hits against the high- and low-iron conditions (25 and
2.5 mM, respectively) yielded a broad range of IC50 shifts,
including instances of a decrease in IC50 at the higher Fe(II)
concentration tested, as well as several increases in IC50 of greater
than 10-fold at the high Fe(II) concentration. As a reference, the
strong iron chelator EDTA was tested and yielded a ratio of 5.9
under these conditions. Furthermore, within series of structurally
similar hits, there were considerable variations in the IC50 shifts for
low/high Fe(II) concentrations. Given these variations and
factoring in the relatively narrow range of boundary iron
concentrations used in this profile (the latter largely being
determined by the need to maintain adequate assay signal), an
overreliance on this filtering step to exclude series from further
consideration carries the risk of losing viable scaffolds. Thus, we
did not exclude hits based on the iron-dependency profile but
noted the ratios as a possible indicator for the compounds’
mechanism of action (for example, the isoquinoline diones series,
Figure 2 and Table S1).
Of the selected 157 hits, 29 representative members were
subjected to an orthogonal MALDI-TOF assay to confirm that
they were genuine demethylase inhibitors and not inhibitors of
FDH. Mass spectrometric assays, which employed micromolar
concentrations of JMJD2E and measured direct depletion of a
trimethylated lysine-substrate (ARKme3STGGK-NH2), con-
firmed most hit series as JMJD2E inhibitors (Table S1). Because
of the need to maintain an adequate signal, the MALDI-TOF
assay utilized a JMJD2E concentration 20-fold higher than that
used in the HTS (2mM); note that this results in decreases in
apparent potency as judged by IC50 values and the inability to
perform curve fitting on some of the responses. Nonetheless, most
Figure 1. Screening and Hit Prioritization Strategy.
doi:10.1371/journal.pone.0015535.g001
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confirming them as bona fide demethylase inhibitors (Figure 2). To
evaluate the potential for promiscuity of inhibition, the hits
presented in Figure 2 were queried against the PubChem
database by noting the instances of an ‘‘active’’ designation versus
the total number of datasets in which a particular compound is
included. The hits were found to be largely inactive in the 200–
400 screens in which they were run, thereby ruling them out as
promiscuous inhibitors. In comparison, the flavonoid quercetin,
which was previously identified as a JMJD2E inhibitor [18], is
reported as being active in 85 assays, inconclusive in 504 assays
and inactive in 202 assays.
Among the inhibitor series identified in the qHTS against
JMJD2E (Figure 2), we selected the 8-hydroxyquinolines (8HQ)
for further investigation, with the aims of understanding basic
structure-activity relationships (SAR), mode of action, and possible
Figure 2. Representative HTS hits. Shown are representative members of clusters along with results from the screen and prioritization
experiments.
doi:10.1371/journal.pone.0015535.g002
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amenable to chemical modification, possesses high ligand
efficiency and, because some 8HQ-derivatives have recently been
identified as inhibitors of the 2OG dependent hypoxia inducible
factor prolyl hydroxylase PHD2 (EGLN1), where both in vitro and
cell-based potency were demonstrated [23,24].
A variety of 8HQ substitution patterns were identified from the
qHTS. Among these, substitution at the 2-positions showed weaker
inhibitory potency, while substitution at the 4-, 5- and 7- positions on
the 8HQ ring appeared to result in greater potency (Figure 3). The
largest number of active analogues were identified within the 5-
substituted series, and here a variety of lipophilic and basic
substituents were tolerated, in addition to the formyl group.
Importantly, note that the trends observed for JMJD2E inhibition
are significantly different from those observed in the recent study by
Smirnova et al. of prolyl hydroxylase inhibitors against the PHD
isoforms; in that study, 8HQs with branched substituents at the 7-
position were among the best hits [24]. Comparison between the 7-
substituted branched 8HQ described in Smirnova et al. and the
present qHTS dataset reveals one direct structural match, SID
14737227: this compound displayed a shallow response and relatively
weak potency against JMJD2E (IC50 of 39 mM, Table S1).
Figure 3. Structure-activity relationships for substituted 8-hydroxyquinolines identified in the qHTS against JMJD2E (qHTS IC50
values derived from the FDH-coupled assay). Some substitution patterns were chosen for further medicinal chemistry; IC50s for these
synthesized compounds are indicated in italics.
doi:10.1371/journal.pone.0015535.g003
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for comparison with the 2,4-PDCA chemotype, the 4- and 5-
carboxy-8HQ analogues were prepared and their identity and
purity verified by standard analytical liquid chromatography
coupled with mass spectrometry (LC-MS) methods (see Materials
and Methods and Text S1 for details). By analogy with 2,4-PDCA
one might expect 4-carboxy-8HQ to bind similarly; however, 5-
carboxy-8HQ (SID 85736331) had greater potency with an IC50
of 200 nM compared to 2 mM for the 4-carboxy isomer SID
85736397 using the FDH coupled assay (Figure 3). Preliminary
kinetic studies suggested possible mixed-mode of inhibition for the
5-carboxy-8-HQ with respect to 2-OG (Figure S2). In part this
might be due to competition not only with 2OG but also with
peptide substrate; however, tight-binding competitive inhibitors
also display mixed-mode inhibition kinetics when the enzyme
concentration used for screening is very close to the apparent Ki.
Thus the IC50 for 5-carboxy-8-HQ was measured at a number of
different enzyme concentrations; the resulting shift in IC50 with
increasing enzyme concentration (Figure S2) suggests that this
compound does display tight-binding inhibitory behaviour. This
may account at least in part for the apparent mixed-mode
inhibition with respect to 2OG.
Crystallography
We were able to crystallize 5-carboxy-8HQ in complex
withJMJD2A to investigate the inhibitor interactions within the
active site environment. The structure revealed that 5-carboxy-
8HQ is positioned in a similar location to the 2OG analogue N-
oxalylglycine in complex with JMJD2A and Ni(II) (which
substitutes for Fe(II)); the 5-carboxy group of 5-carboxy-8HQ
and the C-5 carboxylates are positioned to interact with side
chains Lys 206, Tyr 132. 5-Carboxy-8HQ is also positioned to
coordinate with the active site Ni(II), in a bidentate fashion via its
quinoline-nitrogen and 8-hydroxy group (Figure 4A,B). Com-
parison of the 5-carboxy-8HQ structure with that of JMJD2A in
complex with the H3K9me3 substrate peptide and N-oxalylglycine
Figure 4. JMJD2A crystal structure complexed with 5-carboxy-8-HQ (SID 85736331). (A) activesiteresiduesareingreensticks,5-carboxy-8-
hydroxyquinoline as cyan sticks, secondary structure helices in red and sheets in yellow. The Ni(II) ion (replacing Fe(II)), is a blue sphere and the Zn(II) is a
grey sphere. (B) Bindingmode of 5-carboxy-8-hydroxyquinoline in JMJD2A. Theexperimental 2Fo-Fcelectron density is shown as grey mesh (contoured
at 1s). Hydrogen bonds to residues are shown in black. Hydrogen bonds involving waters (red spheres) are shown in red, distances in A ˚.( C) Overlay of
JMJD2A crystal structure with the 5-carboxy-8-hydroxyquinoline (residues green, compound cyan, Ni(II) in blue) with the crystal structure with 2,4 PDCA
(residues compound and Ni(II) ion are pink, PDB ID: 2VD7). The distances shown are for the 8-hydroxyquinoline structure between: 5-carboxy-8-
hydroxyquinoline and His 276, Ni
2+ and His 188 (in black), His 276 and Ni
2+ (in red). Distances in A ˚.( D) Surface view of superimposition of 8-
hydroxyquinoline5-acid bound JMJD2Astructurewith that ofJMJD2A boundtohistone 3 lysine9 trimethylated(H3K9me3) substratepeptide (greyand
magenta sticks) and the 2-oxoglutarate (2OG) mimetic N-oxalylglycine (NOG, yellow sticks), PDB ID: 2OQ6. Binding of the 8-hydroxyquinoline 5-acid
(cyan sticks) is likely to prevent binding of 2OG but not directly that of the H3K9me3 residue (in magenta) or other residues in the substrate peptide (in
grey). Peptide sequence ARK(me3)STGGK(Ac). Ni
2+ of structure 2OQ6, yellow sphere; Ni
2+ of 8-hydroxyquinoline structure, green sphere. The triad of
metal coordinating residues are in green sticks. Crystallographic data and refinement parameters are described in Table S2.
doi:10.1371/journal.pone.0015535.g004
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likely to compete with binding of 2OG and, at least, not directly
with the peptide substrate (Figure 4D) [13,14,25]. However,
binding of the inhibitor may also indirectly affect substrate
binding; this notion is supported in part by the observation of
mixed mode inhibition kinetics when 5-carboxy-8HQ was tested
with varying concentrations of 2OG (Figure S2). Studies in
solution on other 2OG oxygenases have shown that binding of
inhibitors (and 2OG) can affect the fold away from the active site
[26,27].
An interesting difference between the 5-carboxy-8HQ and 2OG
structures, as compared to structures of JMJD2A with peptide or
other ligands bound (PDB IDs 2WWJ, 2VD7, 2OQ6, 2OQ7), is
that the interaction between the hydroxyl moiety of 5-carboxy-
8HQ and His 276 (distance 2.5 A ˚) appears to replace the ligation
bond between the Ni(II) and His 276, shifting the position of the
Ni(II) ion away from His 276 (by approximately 1.5 A ˚).
Cellular Demethylase Assays
To examine if 5-carboxy-8HQ could also inhibit JMJD2 histone
demethylase activity in cells we needed to develop an assay to
directly measure demethylase activity in vivo. It was previously
demonstrated that overexpression of the JMJD2A histone
demethylase in cultured cells lead to near complete depletion of
cellular H3K9me3 as assessed by indirect immunofluorescence
[28]. Based on these observations, we have designed an in cell
assay to specifically and quantitatively measure inhibition of
JMJD2A histone demethylase activity. To achieve this, a Flag-
tagged version of JMJD2A was transiently overexpressed in HeLa
cells either in the presence of a vehicle control (DMSO), 1 mM
dimethyl-2,4-PDCA (a cell-permeable derivative of 2,4-PDCA),
2.5 mM dimethyloxalylglycine (DMOG, a cell-permeable deriv-
ative of N-oxalylglycine), or varying concentrations of 5-carboxy-8-
HQ. After 24 hours of incubation time cells were fixed and then
analyzed by indirect immunofluoresence with Flag antibody to
identify the cells overexpressing the demethylase and an antibody
recognizing endogenous H3K9me3 to quantify the level of this
histone modification. In order to reliably measure the levels of
demethylase activity in transfected cells, significantly large cell
numbers were required making manual single cell analysis
cumbersome and impractical. Therefore, in order to automate
this process a series of images were collected for each treatment on
a standard epifluorescence microscope (Figure 5A) and then
submitted to CellProfiler Software for analysis [29]. CellProfiler
was configured to analyze the images for DAPI signal, a DNA
stain, enabling the program to identify the location of individual
cells and create a boundary that delineates the volume of the
nuclear compartment. As not all cells in a given field are
transfected, the Flag-JMJD2A-expressing cells were identified by
quantifying the immunofluoresence signal resulting from the Flag
antibody staining and using the mock transfected cells as a baseline
for the signal intensity of non-transfected cells. Once the
transfected cells were identified, the nuclear H3K9me3 immuno-
fluorescence signal for each cell was quantified by CellProfiler.
The levels of H3K9me3 staining intensity were analyzed in the
DMSO vehicle treated or inhibitor treated samples. As a control
and a means of determining maximal possible inhibition of
demethylase activity, cells expressing the JMJD2A H188A
catalytically deficient mutant were also quantified in each
experiment. The level of demethylase activity inhibition by 5-
carboxy-8HQ treatment (Figure 5B, squares) was determined by
quantifying the immunofluoresence signal from the DMSO
treated sample (100% demethylase activity) compared to the
maximal theoretical inhibition signal intensity as determined by
the H3K9me3 signal in cells expressing the catalytically deficient
JMJD2A H188A mutant (0% demethylase activity). For each
treatment a minimum of 400 transfected cells was analyzed and
the final values of inhibition were derived from inhibition
experiments carried out on three separate days (biological
triplicates).
Treatment with increasing 5-carboxy-8HQ (SID 85736331)
concentrations showed a dose-dependent increase in H3K9me3
fluorescence intensity, demonstrating that H3K9me3 demethyla-
tion by JMJD2A is inhibited by 5-carboxy-8HQ in cells
(Figure 5A, 4B &). The cellular IC50 value for 5-carboxy-8-
HQ was determined to be 86.5 mM with standard error of
1.16 mM and 95% confidence interval from 63.74 mMt o
117.3 mM. The 200 mM 5-carboxy-8HQ treatment inhibition of
JMJD2A was greater than treatment with 1 mM PDCA dimethyl
ester or 2.5 mM DMOG indicating that 5-carboxy-8HQ is the
most potent cellular JMJD2A inhibitor identified to date (Figure
S3). Notably, this compound does not require modification to a
‘‘pro-drug’’ ester form in order to be active in cells, as do the
previously reported N-oxalylglycine derivatives [30]. Cytotoxicity
testing of the 5-carboxy-8HQ on HeLa cells was conducted with
the resazurin/resorufin system for cellular metabolism. Cytotox-
icity IC50 was determined to be 291.6 mM( Figure 5B,N) which is
three times the JMJD2A inhibition IC50. At 291.6 mM, JMJD2A
demethylase activity is considered fully inhibited as H3K9me3
levels are comparable to the H188A catalytic JMJD2A mutant
(Figure 5B (&) and Figure S3). Therefore, the 5-carboxy-8HQ
compound functions in a cell to inhibit histone demethylase
activity.
Screening against other 2OG oxygenases
To investigate the effect of substitution on the 8HQ template on
inhibition of individual 2OG oxygenases, selected 8HQ derivatives
were also screened against other human 2OG oxygenases which
have been reported to bind 8HQs. Prolyl Hydroxylase Domain 2
(PHD2) and Factor Inhibiting Hypoxia Inducible Factor (FIH) are
prolyl and asparaginyl hydroxylases, respectively, that regulate the
hypoxic response (for review, see [31]). The compounds in
Figure 6 (representative concentration-response curves and
MALDI-TOF spectra shown in Figure S4) were screened against
JMJD2A, JMJD2E, PHD2 (catalytic domain) and FIH using a
MALDI-TOF-MS-based peptide hydroxylation/demethylation
assay described previously [14]. 2,4-PDCA, a well-characterized
2OG analogue and inhibitor of many 2OG oxygenases
[32,33,34,35], inhibits all the enzymes tested with IC50 values in
the low micromolar range. Notably, although 5-carboxy-8HQ had
a similar potency to 2,4-PDCA against JMJD2E and JMJD2A, it
was less active than 2,4-PDCA against FIH and PHD2, suggesting
that 5-substituted 8HQ may be a relatively preferred template for,
at least, the JMJD2 family of histone demethylases. Testing of this
compound and its future analogues against other subfamilies of
2OG-dependent histone demethylases will be of interest; we
envisage that this will be part of a new study (production of these
enzymes in recombinant form in E. coli has not been reported).
Discussion
We investigated whether a screen of a large-size diverse small
molecule collection could yield novel scaffolds directed at the
histone demethylase family that would be useful in in vitro studies.
Following the initial screen of nearly a quarter of a million
compounds, we carried out a comprehensive filtering strategy in
order to derive high-confidence inhibitor chemotypes for this
family of epigenetic regulators. The results from this screening and
Novel Inhibitors of Jumonji Histone Demethylases
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e15535Figure 5. 5-Carboxy-8-HQ (SID 85736331) increases H3K9me3 levels in HeLa cells through inhibition of JMJD2A. (A) Indirect
immunofluorescence with anti-Flag (green), anti-H3K9me3 (red), and DAPI staining (blue) in HeLa cells overexpressing Flag-tagged JMJD2A. DMSO
solvent treatment has no effect on JMJD2A demethylase activity (white arrows) while increasing concentrations of 5-carboxy-8-hydroxyquinoline
treatment (100 mM to 300mM range shown) resulted in gradual increases in H3K9Me3 levels. The JMJD2A H188A enzymatic mutant does not affect
H3K9Me3 levels when overexpressed. (B) Quantitation of H3K9me3 levels is shown as squares (&). Standard deviations are derived from biological
triplicates at inhibitor concentrations of 20 mM, 50 mM, 100 mM, 200 mM, 300 mM, and 400 mM treatments. Cytotoxicity (N) was assayed at 50 mM,
100 mM, 200 mM, 300 mM, 400 mM, 500 mM, 750 mM, 1 mM, 1,25 mM, 1.5 mM, 1.75 mM, 2 mM, 2.5 mM, and 3 mM.
doi:10.1371/journal.pone.0015535.g005
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(PubChem), with the aim of providing the research community
with a wide range of leads for the development of improved
agents.
In the present study, we selected one series, the 8-hydro-
xyquinolines, for further investigations, including preliminary SAR
investigations which yielded an analogue with improved potency.
X-ray crystallography was used to rationalize the mode of action
of this novel demethylase-directed scaffold: 5-carboxy-8HQ
occupies the 2OG binding site, and kinetic data indicate that it
may indirectly affect the binding of the peptide substrate. A
comparison between the present structure and structures of
JMJD2A with substrates or other ligands, such as 2,4-PDCA,
highlights a notable difference in the ligation of the active-site
metal and the His276 residue: the hydroxyl group from the
inhibitor interacts with His276 while the nickel ion (substitution for
iron) formerly bound to the same His is now shifted away from
that amino acid. Although it is unclear whether the observed shift
in metal position occurs in solution with Fe(II) complexed at the
active site, it highlights the possibility that inhibition of 2OG
oxygenases by metal-chelation at their active sites may involve
movement of the metal.
Our findings, and those of others [23,36], demonstrate that
8HQ may provide an attractive generic template for generating
inhibitors of 2OG oxygenases, and that inhibitory selectivity can
be achieved through substitutions to the 8HQ core. This proposal
is supported by the distinct patterns of 8HQ substitution
determined to be important for JmjC-domain demethylase activity
here (Figure 3) and the recent study of Smirnova et al. where a
branched substituent at the 7-position was found to be important
for 8HQ activity against the related PHDs. It is anticipated that
further medicinal chemistry efforts supported by structure-based
design will thus enable increases in inhibitor potency and
selectivity amongst 2OG oxygenases, and potentially among the
different histone demethylase subfamilies.
Finally, having verified the 8HQ mode of interaction with the
demethylase targets in vitro, we evaluated the effect of 5-carboxy-
8HQ on histone demethylase activity inside cells. Unlike the cases
of histone methyltransferases or histone deacetylases where
multiple examples of loci under direct control of the corresponding
HMTs or HDACs exist, there is no good target gene-based system
for histone demethylase studies. We therefore developed a
transfection-based assay to test the inhibitor’s effect within the
context of a selectively-upregulated demethylase. Changes in
K9me3 levels can only be mediated by inhibition of JMJD2
demethylases (no other demethylases identified to date are capable
of demethylating K9me3) and because the assay quantitates the
degree of histone trimethylation at the H3K9 locus only within
cells that overexpress demethylase, this measurement is relatively
insensitive to the potential effects of the small molecule on the level
of transcription of the underlying gene or on other targets within
the cell. In the assay, the present 5-carboxy-8HQ inhibitor
displayed a strong concentration-dependent effect, restoring the
trimethylation pattern at the H3K9 locus in cells overexpressing
the JMJD2A/KDM4A demethylase. Prior to this work, inhibition
of demethylase activity had only been shown using weak
nonselective agents, such as DMOG (pro-drug form), at millimolar
doses. The 40-fold stronger potency of the present lead, combined
with its improved selectivity profile in vitro and the availability of a
range of analogues, are expected to make this compound a good
starting point for the development of a potent and selective agent
to study epigenetic regulation in cellular context.
Materials and Methods
Reagents
Ferrous ammonium sulfate (FAS), (+)-sodium L-ascorbate (SA),
b-nicotinamide adenine dinucleotide hydrate (NAD
+), Tween-20,
formaldehyde dehydrogenase from Pseudomonas putida (FDH), and
disodium 2OG were from Sigma-Aldrich (St. Louis, MO).
Dimethylsulfoxide certified ACS grade (DMSO) was from Fisher,
Inc. HEPES buffer was obtained from Gibco. The trimethylated
histone peptide substrate ARK(me3)STGGK was synthesized and
HPLC-purified either in-house using a CS-Bio CS336S automated
peptide synthesizer or by the Tufts University Core Facility
(Boston, MA). Synthetic methods for the preparation of 4-carboxy-
8-hydroxyquinoline and 5-carboxy-8-hydroxyquinoline are pro-
vided in Text S1. Black solid-bottom 1,536-well assay plates were
from Greiner Bio-One (Monroe, NC).
Enzymes
The catalytic domain of human JMJD2E (residues 1–337) was
produced as an N-terminally His6-tagged protein in E. coli, and
purified by Ni-affinity chromatography and size-exclusion chro-
matography, and stored at a concentration of 60 mg/mL in
HEPES 50 mM NaCl 500 mM pH 7.5, as reported [13].
JMJD2A was expressed and purified as reported [25]. Factor
Inhibiting Hypoxia Inducible Factor (FIH) was prepared by Ni
affinity followed by gel filtration chromatography [37] and Prolyl
Hydroxylase Domain 2 (PHD2)
181–486 was prepared by cation
exchange chromatography followed by gel filtration chromatog-
raphy as described [38].
Compound library and quantitative high-throughput
screen (qHTS)
A library of 236,376 structurally diverse compounds was tested
for JMJD2E inhibition. Compounds were serially diluted 1:5 in
Figure 6. Inhibitor screening against JMJD2 and other human
2OG oxygenases. IC50 values from MALDI-TOF MS assay. See Figure
S4 for representative concentration-response curves and MALDI-TOF
mass spectra.
doi:10.1371/journal.pone.0015535.g006
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formatted in 1536-well plates. The library comprised the
Molecular Libraries Small Molecule Repository (MLSMR,
http://mlsmr.glpg.com/MLSMR_HomePage/), as well as several
sets of bioactive molecules, approved drugs, and various diverse
collections. Details on the composition of the screening library and
on the preparation of the library for qHTS are provided elsewhere
[39]. JMJD2E-catalyzed (100 nM) demethylation of a trimethy-
lated histone H3 peptide was measured in the presence of the
potential inhibitor (3.7 nM–57 mM) as reported [18] in a
fluorescence-based enzymatic assay using the coupling enzyme
formaldehyde dehydrogenase (FDH) [20]. Compounds were
added by pintool transfer of 23 nL stock in DMSO to 3 mLo f
enzyme in 50 mM HEPES buffer, pH 7.5, containing 0.01%
Tween-20 dispensed in black solid-bottom 1536-well plates (final
0.67% DMSO) and pre-incubated for 15 min. Reactions were
initiated with 1 mL addition of peptide substrate solution
containing final concentrations of 10 mM FAS, 50 mM 2OG,
0.25 U/mL FDH, 0.25 mM NAD
+, and 50 mM peptide substrate
(ARK(me3)STGGK). A ViewLux imager (PerkinElmer, Waltham,
MA) was used to measure NADH fluorescence (lex 340 nm, lem
450 nm) immediately after substrate addition and following
30 min incubation at room temperature. To record any systematic
drifts in assay behavior (signal window and noise), assay plates
containing no library compounds but only DMSO as a vehicle
control were tested periodically (every ,60 plates) throughout the
screen. The screen was conducted on a fully-integrated robotic
system (Kalypsys, Inc., San Diego, CA) as described in detail
elsewhere [40].
Data were normalized to the basal response (0% activity) in the
absence of enzyme and the maximal response (100% activity) in the
absence of compound. Using the Hill equation, dose-response
curves and IC50 values were automatically generated for each
compound tested with software developed internally (www.ncgc.
nih.gov/pub/openhts/curvefit/). Clustering of active compounds
by structural similarity was performed using Leadscope Hosted
Client (Leadscope Inc., Columbus, OH). The initial well fluores-
cence (first kinetic read) associated with each sample was stored in a
database and used in the cheminformatics analysis to identify
autofluorescent compounds interfering with the assay signal.
Hit Confirmation
To minimize the possibility of false positives arising through
inhibition of the FDH coupling enzyme, active compounds were
tested in a reaction containing 0.025 U/mL FDH enzyme and the
substrates 0.25 mM NAD
+ and 10 mM formaldehyde, using a
fluidic protocol identical to that used for qHTS. Compounds were
also tested for their potential to act as iron chelators in solution by
measuring inhibition of JMJD2E activity under both high and low
iron conditions (25 and 2.5 mM Fe(II), respectively). The ratio of
IC50 values under high iron to low iron was calculated for each
compound. Compounds that exhibited ratios .3.0 were identified
as potential chelators, where the ratio of 3.0 was based arbitrarily
on the ratio of 5.9 obtained for the strong iron chelator EDTA.
Matrix-Assisted Laser Desorption/Ionization-Time-of-
flight (MALDI-TOF) Mass Spectrometry
JMJD2 assays were carried out as reported [13]. In brief, an
assay reaction consisted of JMJD2 (1 mM (Figure 5) or 2 mMi n
qHTS hit confirmation (Table S1)), FAS (10 mM), SA (100 mM),
2OG (10 mM) ARK(me3)STGGK peptide (10 mM), in 50 mM
HEPES (pH 7.5) with varying concentrations of inhibitors (final
DMSO concentration was 5%). Initially, JMJD2, Fe(II), ascorbate
and inhibitors were pre-incubated for 15 min prior to the addition
of peptide and 2OG. The reaction was incubated for 30 min
before 1:1 quenching with methanol followed by addition of four
volumes of 20 mM triammonium citrate. PHD2 and FIH assays
were carried out as described [41,42] with minor modifications.
PHD2 assay consisted of PHD2 (1 mM), FAS (10 mM), SA
(100 mM), 2OG (60 mM) and HIF-1a
556–574CODD peptide
(50 mM), in 50 mM HEPES (pH 7.5) with varying concentrations
of inhibitors (final DMSO concentration was 5%). Initially, PHD2,
Fe(II), ascorbate and inhibitors were pre-incubated for 15 min
prior to the addition of peptide and 2OG. The reaction was
incubated for 30 min before 1:1 quenching with 1% TFA followed
by addition of three volumes of 20 mM triammonium citrate. FIH
assay consisted of FIH (1 mM), FAS (10 mM), SA (100 mM), 2OG
(100 mM) and HIF-1a
786–826CAD peptide (100 mM), in 50 mM
HEPES (pH 7.5) with varying concentrations of inhibitors (final
DMSO concentration was 5%). Initially, FIH, Fe(II), ascorbate,
and inhibitors were pre-incubated for 15 min prior to the addition
of peptide and 2OG. The reaction was incubated for 30 min
before 1:1 quenching with 200 mM HCl followed by addition of
two volumes of dH2O. The diluted assay mixture (1 mL) from
JMJD2 and PHD2 assays were mixed with 1 mLo fa-cyano-4-
hydroxycinnamic acid and 1 mL of FIH assay mixture was mixed
with 1 mL of sinapinic acid matrix, and assessed by matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF).
Crystallography
JMJD2A was diluted with gel filtration buffer (10 mM HEPES
pH 7.5, 500 mM NaCl and 5% glycerol) to a concentration of
10 mM (0.5 mg/mL). The 5-carboxy-8-HQ was added to the
protein solution to a final concentration of 100 mM (0.1%
DMSO). The solution was then concentrated in a 4 ml centrifugal
concentrator (Centricon
TM, Millipore, MWC 10 kDa) to a final
protein concentration of 250 mM (11 mg/mL). This solution was
then used for crystallization trials. Crystals were grown by vapor
diffusion at 4uC in 300 nL sitting drops with a 1:2 ratio of protein
to well solution (100 mM Na citrate pH 5.5, 4 mM NiCl2 and
20% w/v PEG 3350). Crystals were cryoprotected by transferring
to a solution of mother liquor supplemented with 2 mM 5-
carboxy-8-hydroxyquinoline and 25% v/v glycerol before being
flash frozen in liquid N2. Data were collected from a single crystal
at 100 K at the Diamond Light Source, beamline I04 using a
beam with wavelength 0.97630 A ˚. The data were processed with
iMOSFLM [43] and SCALA [44] followed by molecular
replacement using Phaser [45]. Refinement was carried out with
PHENIX (version 1.6) [46] with iterative rebuilding of the model
using Coot [47]. The Final R and Rfree values were 18.0% and
22.6% respectively. All residues were in acceptable regions of a
Ramachandran plot as calculated by MolProbity [48]. Crystallo-
graphic statistics are shown in Table S2.
Cellular Demethylase Assay
HeLa cellswere maintained inDMEMmediasupplementedwith
10% FBS and penicillin/streptomycin. Cells were transiently
transfected with either Flag-tagged JMJD2A or the H188A catalytic
mutant of JMJD2A using Fugene HD. Inhibition studies were
initiated 4 hr after cellular transfection and compounds were added
to a final concentration of 20–400 mM in 0.5% DMSO. H3K9me3
levels were measured using immunofluorescence staining as
described [28] in cells following 24 hr incubation with compound.
All cells were stained with an anti-Flag mouse monoclonal antibody
(M2; Sigma F1804), rabbit anti-H3K9me3 (Abcam Ab8898), and
DAPI for DNA. FITC conjugated mouse and Rhodamine
conjugated rabbit secondary antibodies were used to fluorescently
label the Flag and H3K9me3 primary antibodies. Image analysis
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identified as those cells with higher Flag immunofluorescence than
mock transfected cells. Data were normalized by setting DMSO
treated JMJD2A transfected cells to 100% demethylase activity and
the catalytic mutant H188A transfected cells to 0% activity. The
data shown are averages of 3 or more biological replicates per
concentration. Cytotoxicity testing was done with CellTiter-Blue
(Promega) according to the manufacturer’s directions.
Supporting Information
Figure S1 HTS statistical performance. A robust Z9 factor
was maintained throughout the HTS for JMJD2E inhibitors.
(PDF)
Figure S2 Kinetics and Mode of Inhibition of 5-carboxy-
8-8HQ against JMJD2E. FDH assay was carried out at 2mM
JMJD2E, 200 mM ARK(me3)STGGK peptide (excess of Km) and
varying 2OG concentrations.
(PDF)
Figure S3 Cell-based demethylation assay. (A) Quantita-
tion of H3K9me3 levels. 5-Carboxy-8-hydroxyquinoline (SID
85736331) treatments were at 20mM, 50mM, 100mM, 200mM,
300mM, and 400mM compared to 2.5mM Dimethyloxalylglycine
(DMOG) and 1mM dimethyl-2,4-PDCA. Treatment with 200mM
5-carboxy-8HQ inhibited JMJD2A demethylase activity to
approximately 10% which is greater than treatment with either
2.5mM DMOG (approximately 20% activity) or 1mM dimethyl-
2,4-PDCA (approximately 35% activity). (B) Indirect immunoflu-
orescence with anti-Flag (green), anti-H3K9me3 (red), and DAPI
staining (blue) for DNA in HeLa cells overexpressing Flag-tagged
JMJD2E or JMJD2E catalytic mutant.
(PDF)
Figure S4 Inhibitor screening against JMJD2 and other
human 2OG oxygenases. (A) Representative IC50 curve for
JMJD2A inhibition by SID 85736331. (B) Representative
MALDI-TOF mass spectrum for JMJD2A demethylation reac-
tions by MALDI-TOF MS at different inhibitor concentrations.
(PDF)
Table S1 Inhibitory activities of HTS Hits. Provided as a
separate Excel spreadsheet.
(XLSM)
Table S2 Crystallographic data and refinement param-
eters.
(DOC)
Text S1 Synthetic and Analytical Procedures.
(DOC)
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